helmholtzeyeinstituteРоссийский офтальмологический журналRussian Ophthalmological Journal2072-00762587-5760Real time Publishers10.21516/2072-0076-2022-15-1-7-12helmholtzeyeinstitute-880Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDIESМикроРНК — биомаркер агрессивности меланомы хориоидеиMicroRNA - biomarker of aggressiveness of choroidal melanomahttps://orcid.org/0000-0001-6870-1952БровкинаА. Ф.BrovkinaA. F.

Алевтина Федоровна Бровкина — академик РАН, д-р мед. наук, профессор, профессор кафедры офтальмологии; врач-офтальмолог онкологического отделения

ул. Баррикадная, д. 2/1, Москва, 123995

2-й Боткинский пр-д, д. 5, Москва, 125284

Alevtina F. Brovkina - Academician of RAS, Dr. of Med. Sci., professor, professor at the department of ophthalmology, ophthalmologist at the oncology department

2/1, Barrikadnaya st., Moscow, 123995

5, 2nd Botkinsky proezd, Moscow, 125284

https://orcid.org/0000-0003-2525-3082ЦыбиковаН. Д.TsybikovaN. D.

Наталья Дашазэгбэевна Цыбикова - аспирант кафедры офтальмологии1, врач-офтальмолог поликлинического отделения № 2

ул. Баррикадная, д. 2/1, Москва, 123995

2-й Боткинский пр-д, д. 5, Москва, 125284

Natalia D. Tsybikova - PhD student, department of ophthalmology, ophthalmologist at the polyclinic department no. 2

2/1, Barrikadnaya st., Moscow, 123995

5, 2nd Botkinsky proezd, Moscow, 125284

 

natashatd@bk.ruФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; Московский городской офтальмологический центр «ГБУЗ "Городская клиническая больница им. С.П. Боткина"» Департамента здравоохранения города МосквыРоссияRussian Medical Academy of Continuous Professional Education; Botkin HospitalRussian Federation202225032022151712Copyright © Бровкина А.Ф., Цыбикова Н.Д., 20222022Бровкина А.Ф., Цыбикова Н.Д.Brovkina A.F., Tsybikova N.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://roj.igb.ru/jour/article/view/880

Почти 50 % микроРНК (семейство малых некодирующих РНК) связаны с участками генома, отвечающими за развитие опухолей, исполняя роль онкогенов или генов-супрессоров опухоли. В 2008 г. появились сообщения о возможности использования микроРНК в качестве прогностического биомаркера риска метастазирования увеальной меланомы. Первоначально исследовали микроРНК в образцах меланомы, позднее была показана возможность использования для этих целей плазмы крови.Цель работы - изучить характер экспрессии микроРНК-146а, микроРНК-155, микроРНК-223, микроРНК-126, микроРНК-27b, циркулирующих в плазме крови больных меланомой хориоидеи (МХ), и определить их значимость в прогнозировании возможных гематогенных метастазов.Материал и методы. В исследование включены 84 больных МХ 35–86 лет (в ср. 63,4 ± 1,2 года). Толщина МХ варьировала в пределах 0,77–17,19 мм (в ср. 7,21 ± 0,43 мм). Контрольную группу составили 28 волонтеров 45–78 лет (в ср. 62,90 ± 1,42 года). Уровни экспрессии микроРНК, циркулирующих в плазме крови, определяли методом количественной полимеразной цепной реакции.Результаты. Показано увеличение уровня экспрессии микроРНК-155, микроРНК-146а, микроРНК-126, микроРНК-223 и микроРНК-27b, циркулирующих в плазме крови, у всех 84 больных МХ по сравнению с контрольной группой.Заключение. Исследование уровня микроРНК (микроРНК-146, микроРНК-155, микроРНК-223, микроРНК-126 и микроРНК-27b) в плазме крови больных МХ может быть использовано как для подтверждения диагноза МХ в трудных диагностических случаях, так и для определения агрессивности течения опухоли и прогнозирования скрытого метастазирования.

Almost 50 % of microRNAs (a family of small noncoding RNAs) are associated with the regions of the genome responsible for the development of tumors. These microRNAs play the role of oncogenes or tumor suppressor genes. In 2008, there were reports of the possibility of using microRNA as a predictive biomarker of the metastatic risk of uveal melanoma. Initially, microRNAs were investigated in melanoma samples; later, the possibility of using blood plasma for these purposes was shown.Purpose: to study the character of expression of miRNA- 146a, miRNA-155, miRNA-223, miRNA-126, miRNA-27b in the blood plasma of patients with choroidal melanoma (CM) and determine their significance in predicting possible hematogenous metastases.

Material and methods. The study included 84 patients with CM aged 35–86 (ave 63.4 ± 1.2 yrs). The thickness of the CM varied in the range of 0.77–17.19 mm (ave 7.21 ± 0.43 mm). The control group consisted of 28 volunteers aged 45-78 (62.90 ± 1.42 yrs). MicroRNA expression levels were determined by quantitative PCR.Results. An increase in the expression level of miRNA-155, miRNA-146a, miRNA-126, miRNA-223, and miRNA-27b in blood plasma in all 84 patients with CM was revealed.Conclusion. The study of miRNA levels (miRNA-146, miRNA-155, miRNA-223, miRNA-126 and miRNA-27b) in the blood plasma of patients with CM can be used both to confirm the diagnosis of CM in difficult diagnostic cases and to determine the aggressiveness of the course tumor and prediction of metastasis.

меланома хориоидеимикроРНК-146амикроРНК-155микроРНК-223микроРНК-126микроРНК-27bбиомаркерchoroidal melanomamiRNA-146amiRNA-155miRNA-223miRNA-126miRNA-27bbiomarkerReferencesCarvajal R.D., Schwartz G.K., Tezel T., et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br. J. Ophthalmol. 2017; 101 (1): 38–44. doi: 10.1136/bjophthalmol-2016-309034Carvajal R.D., Schwartz G.K., Tezel T., et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br. J. Ophthalmol. 2017; 101 (1): 38–44. doi: 10.1136/bjophthalmol-2016-309034Maheshwari A., Finger P.T. Cancers of the eye. Cancer Metastasis Rev. 2018; 37 (4): 677–90. doi: 10.1007/s10555-018-9762-9Maheshwari A., Finger P.T. Cancers of the eye. Cancer Metastasis Rev. 2018; 37 (4): 677–90. doi: 10.1007/s10555-018-9762-9Helgadottir H., Höiom V. The genetics of uveal melanoma: current insights. Appl. Clin. Genet. 2016; 9: 147–55. doi:10.2147/TACG.S69210Helgadottir H., Höiom V. The genetics of uveal melanoma: current insights. Appl. Clin. Genet. 2016; 9: 147–55. doi:10.2147/TACG.S69210Virgili G., Gatta G., Ciccolallo L., et al. EUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114 (12): 2309–15. doi:10.1016/j.ophtha.2007.01.032Virgili G., Gatta G., Ciccolallo L., et al. EUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114 (12): 2309–15. doi:10.1016/j.ophtha.2007.01.032Park S.J., Oh C.M., Kim B.W., et al. Nationwide incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999–2011). Invest. Ophthalmol. Vis. Sci. 2015; 56 (8): 4719–24. doi:10.1167/iovs.15-16532Park S.J., Oh C.M., Kim B.W., et al. Nationwide incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999–2011). Invest. Ophthalmol. Vis. Sci. 2015; 56 (8): 4719–24. doi:10.1167/iovs.15-16532Singh N., Seregard S, Singh A.D. Uveal melanoma: epidemiologic aspects. In: Damato B., Singh A. (eds). Clinical Ophthalmic Oncology. Springer, Cham: 53-69. https://doi.org/10.1007/978-3-030-17879-6_4Singh N., Seregard S, Singh A.D. Uveal melanoma: epidemiologic aspects. In: Damato B., Singh A. (eds). Clinical Ophthalmic Oncology. Springer, Cham: 53-69. https://doi.org/10.1007/978-3-030-17879-6_4Бровкина А.Ф. Локальное лечение меланом хориоидеи: возможности и ограничения. Вестник офтальмологии. 2018; 134 (4): 52–60.Brovkina A.F. Local treatment of choroidal melanoma: possibilities and limitations. Vestnik oftal’mologii. 2018; 134 (4): 52–60 (in Russian). doi: 10.17116/oftalma201813404152Damato E.M., Damato B.E. Detection and time to treatment of uveal melanoma in the United Kingdom: аn evaluation of 2,384 patients. Ophthalmology. 2012; 119 (8):1 582–1589. doi:10.1016/j.ophtha.2012.01.048Damato E.M., Damato B.E. Detection and time to treatment of uveal melanoma in the United Kingdom: аn evaluation of 2,384 patients. Ophthalmology. 2012; 119 (8):1 582–1589. doi:10.1016/j.ophtha.2012.01.048Singh A.D., Turell M.E., Topham A.K. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118 (9): 1881–5. doi: 10.1016/j.ophtha.2011.01.040Singh A.D., Turell M.E., Topham A.K. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118 (9): 1881–5. doi: 10.1016/j.ophtha.2011.01.040AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer’s 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol. 2015; 133 (4): 376–83. doi: 10.1001/jamaophthalmol. 2014.5395AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer’s 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol. 2015; 133 (4): 376–83. doi: 10.1001/jamaophthalmol. 2014.5395Nezu N., Goto H., Umazume K., et al. Clinical analysis of uveal melanoma. Nippon Ganka Gakkai Zasshi. 2017; 121 (5): 413–8.Nezu N., Goto H., Umazume K., et al. Clinical analysis of uveal melanoma. Nippon Ganka Gakkai Zasshi. 2017; 121 (5): 413–8.Bellerive C., Ouellet E., Kamaya A., Singh A.D. Liver imaging techniques: recognition of uveal melanoma metastases. Ocul. Oncol. Pathol. 2018; 4 (4): 254–60. doi: 10.1159/000485424Bellerive C., Ouellet E., Kamaya A., Singh A.D. Liver imaging techniques: recognition of uveal melanoma metastases. Ocul. Oncol. Pathol. 2018; 4 (4): 254–60. doi: 10.1159/000485424Гришина Е.Е., Степанова Е.А., Богатырев А.М. Диагностика метастатической увеальной меланомы. Что изменилось за 10 лет? Альманах клинической медицины. 2019; 47 (8): 712–20.Grishina E.E., Stepanova E.A., Bogatyrev A.M. The diagnosis of metastatic uveal melanoma. What has changed during 10 years? Almanac of Clinical Medicine. 2019; 47 (8): 712–20 (in Russian). doi: 10.18786/2072-0505-2019-47-050Diener-West M., Reynolds S.M., Agugliaro D.J., et al. Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch. Ophthalmol. 2005; 123 (12): 1639–43. doi: 10.1001/archopht.123.12.1639Diener-West M., Reynolds S.M., Agugliaro D.J., et al. Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch. Ophthalmol. 2005; 123 (12): 1639–43. doi: 10.1001/archopht.123.12.1639Peng Y., Croce C.M. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016; 1: 15004. doi:10.1038/sigtrans.2015.4Peng Y., Croce C.M. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016; 1: 15004. doi:10.1038/sigtrans.2015.4Kozomara A., Birgaoanu M., Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019; 47 (1): 155–62. doi: 10.1093/nar/gky1141Kozomara A., Birgaoanu M., Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019; 47 (1): 155–62. doi: 10.1093/nar/gky1141Worley L.A., Long M.D., Onken M.D., Harbour J.W. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Research. 2008; 18 (3): 184–90. doi: 10.1097/CMR.0b013e3282feeac6Worley L.A., Long M.D., Onken M.D., Harbour J.W. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Research. 2008; 18 (3): 184–90. doi: 10.1097/CMR.0b013e3282feeac6Radhakrishnan A., Badhrinarayanan N., Biswas J., Krishnakumar S. Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. Mol. Vis. 2009; 15: 2146–54. PMID: 19898689Radhakrishnan A., Badhrinarayanan N., Biswas J., Krishnakumar S. Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. Mol. Vis. 2009; 15: 2146–54. PMID: 19898689Aughton K., Kalirai H., Coupland S.E. MicroRNAs and uveal melanoma: understanding the diverse role of these small molecular regulators. Int. J. Mol Sci. 2020; 21 (16): 5648. doi:10.3390/ijms21165648Aughton K., Kalirai H., Coupland S.E. MicroRNAs and uveal melanoma: understanding the diverse role of these small molecular regulators. Int. J. Mol Sci. 2020; 21 (16): 5648. doi:10.3390/ijms21165648Achberger S., Aldrich W., Tubbs R., et al. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol. Immunol. 2014; 58 (2): 182–86. doi:10.1016/j.molimm.2013.11.018Achberger S., Aldrich W., Tubbs R., et al. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol. Immunol. 2014; 58 (2): 182–86. doi:10.1016/j.molimm.2013.11.018Li Z., Yu X., Shen J., Jiang Y. MicroRNA dysregulation in uveal melanoma: а new player enters the game. Oncotarget. 2015; 6 (7): 4562–8. doi:10.8632/оncotarget.2923Li Z., Yu X., Shen J., Jiang Y. MicroRNA dysregulation in uveal melanoma: а new player enters the game. Oncotarget. 2015; 6 (7): 4562–8. doi:10.8632/оncotarget.2923Triozzi P.L., Achberger S., Aldrich W., et al. Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma. Clin. Epigenetics. 2016; 8: 80. doi: 10.1186/s13148-016-0243-0Triozzi P.L., Achberger S., Aldrich W., et al. Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma. Clin. Epigenetics. 2016; 8: 80. doi: 10.1186/s13148-016-0243-0Russo A., Caltabiano R., Longo A., et al. Increased Levels of miRNA-146a in serum and histologic samples of patients with uveal melanoma. Front Pharmacol. 2016; 7: 424. doi: 10.3389/fphar.2016.00424Russo A., Caltabiano R., Longo A., et al. Increased Levels of miRNA-146a in serum and histologic samples of patients with uveal melanoma. Front Pharmacol. 2016; 7: 424. doi: 10.3389/fphar.2016.00424Rodríguez M.F.B., Fernandez M.B., Baameiro L.N., et al. Blood biomarkers of uveal melanoma: current perspectives. Clin. Ophthalmol. 2020; 14: 157–69. doi: 10.2147/OPTH.S199064Rodríguez M.F.B., Fernandez M.B., Baameiro L.N., et al. Blood biomarkers of uveal melanoma: current perspectives. Clin. Ophthalmol. 2020; 14: 157–69. doi: 10.2147/OPTH.S199064Iorio M.V., Croce C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 2017; 9 (6): 852–8. doi: 10.15252/emmm.201707779Iorio M.V., Croce C.M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 2017; 9 (6): 852–8. doi: 10.15252/emmm.201707779Zhang R., Zhang L.J., Yang M.L., et al. Potential role of microRNA-223-3p in the tumor genesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics. Mol. Med. Rep. 2018; 17 (2): 2211–28. doi: 10.3892/mmr.2017.8167Zhang R., Zhang L.J., Yang M.L., et al. Potential role of microRNA-223-3p in the tumor genesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics. Mol. Med. Rep. 2018; 17 (2): 2211–28. doi: 10.3892/mmr.2017.8167Bao J., Yu Y., Chen J., et al. MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis. 2018; 9 (10): 1045. doi: 10.1038/s41419-018-1020-0Bao J., Yu Y., Chen J., et al. MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis. 2018; 9 (10): 1045. doi: 10.1038/s41419-018-1020-0Miguel D., de Frutos-Baraja J.M., López-Lara F., et al. Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after episcleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I. J. Contemp. Brachytherapy. 2018; 10 (4): 337–46. doi: 10.5114/jcb.2018.77849Miguel D., de Frutos-Baraja J.M., López-Lara F., et al. Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after episcleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I. J. Contemp. Brachytherapy. 2018; 10 (4): 337–46. doi: 10.5114/jcb.2018.77849Wu T., Lin Y., Xie Z. MicroRNA-1247 inhibits cell proliferation by directly targeting ZNF346 in childhood neuroblastoma. Biol. Res. 2018; 51 (1): 13. doi:10.1186/s40659-018-0162уWu T., Lin Y., Xie Z. MicroRNA-1247 inhibits cell proliferation by directly targeting ZNF346 in childhood neuroblastoma. Biol. Res. 2018; 51 (1): 13. doi:10.1186/s40659-018-0162у

The authors declare that there are no conflicts of interest present.